Projecten per jaar
Persoonlijk profiel
Expertise
Project: " Targeting of tumor subpopulations in Multiple Myeloma: protein/gene expression analysis of residual cancer cells and targeting of these cells using nanobodies"
I obtained a Master in Biomedical Sciences at the Free University of Brussels (Vrije Universiteit Brussel, VUB) in 2011. I started my PhD in the lab of Hematology and Immunology (HEIM) under the supervision of Prof. Karin Vanderkerken focusing on the role of the bone marrow microenvironment in multiple myeloma drug resistance. I participated in an EU FP7 project (OVER-MyR) and investigated different cell types that contribute to myeloma disease including myeloid-derived suppressor cells (supervised by Prof. Els Van Valckenborgh), cancer associated fibroblasts (supervised by Prof. Eline Menu and Prof. Angelo Vacca) and mesenchymal stromal cells (supervised by Prof. Ivan Van Riet). In 2016, I obtained a FWO grant to continue my work as a post-doctoral researcher at the HEIM department and in 2018I became assistant professor (10%) at the VUB.
My project focuses on the use of antigen-specific nanobodies to target residual disease in myeloma and prevent relapse of patients. In collaboration with Prof Peter Croucher (Garvan Institute, Sydney, Australia), we investigate myeloma cell dormancy in vitro and in vivo. Nationally, I closely collaborate with Profs Nick Devoogdt and Matthias D’Huyvetter for the development and characterization of AXL- and CS1 specific nanobodies to target minimal residual disease in myeloma by targeted radionuclide therapy (TRNT).
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Kim De Veirman actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Samenwerkingen en hoofdonderzoeksgebieden uit de afgelopen vijf jaar
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
-
ANI322: NANO-AXL: Nanobody-gebaseerde beeldvorming en targeting van AXL positieve tumorcellen in Acute Myeloïde Leukemie en Multiple Myeloma.
1/01/23 → 31/12/26
Project: Fundamenteel
-
ANI323: Gepersonaliseerde tumor-afgeleide dendritische celtherapie om restziekte bij multipel myeloom te overwinnen
1/11/22 → 31/10/23
Project: Fundamenteel
-
FWOAL1045: Gepersonaliseerde therapie gericht tegen het AXL eiwit voor de behandeling van acute myeloide leukemie en multipel myeloom
De Veirman, K., Devoogdt, N. & Vanderkerken, K.
1/01/22 → 31/12/25
Project: Fundamenteel
-
FWOTM1002: Het bestrijden van residuele ziekte in Multipel Myeloom met behulp van op Nanobody-gebaseerde therapieën
1/10/20 → 31/12/23
Project: Fundamenteel
Onderzoeksoutput
-
Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis
Van der Vreken, A., Oudaert, I., Ates, G., Faict, S., Vlummens, P., Satilmis, H., Fan, R., Maes, A., Massie, A., De Veirman, K., De Bruyne, E., Vanderkerken, K. & Menu, E., 28 mrt 2023, In: Journal of pathology. 260, 2, blz. 112-123 12 blz.Onderzoeksoutput: Article › peer review
1 Citaat (Scopus) -
S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma
Wang, Y., Muylaert, C., Wyns, A., Vlummens, P., De Veirman, K., Vanderkerken, K., Zaal, E., Berkers, C., Moreaux, J., De Bruyne, E. & Menu, E., 20 jul 2023, (E-pub ahead of print) In: Haematologica.Onderzoeksoutput: Article › peer review
-
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
Ertveldt, T., Krasniqi, A., Ceuppens, H., Puttemans, J., Dekempeneer, Y., De Jonghe, K., de Mey, W., Lecocq, Q., De Vlaeminck, Y., Awad, R. M., Goyvaerts, C., De Veirman, K., Morgenstern, A., Bruchertseifer, F., Keyaerts, M., Devoogdt, N., D'Huyvetter, M. & Breckpot, K., 1 mei 2023, In: Journal of Nuclear Medicine. 64, 5, blz. 751-758 8 blz.Onderzoeksoutput: Article › peer review
2 Citaten (Scopus) -
Targeting DNMT3B impairs multiple myeloma cell proliferation and clonogenic capacity and enhances sensitivity to standard of care agents.
Muylaert, C., Van Hemelrijck, L. A., Alaterre, E., Robert, N., Requirand, G., De Veirman, K., Menu, E., Vanderkerken, K., Moreaux, J. & De Bruyne, E., sep 2023.Onderzoeksoutput: Poster
-
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment
Egan, H., Treacy, O., Lynch, K., Leonard, N. A., O'Malley, G., Reidy, E., O'Neill, A., Corry, S. M., De Veirman, K., Vanderkerken, K., Egan, L. J., Ritter, T., Hogan, A. M., Redmond, K., Peng, L., Che, J., Gatlin, W., Jayaraman, P., Sheehan, M., Canney, A. & 5 anderen, , mei 2023, In: Cell Reports. 42, 5, 1 blz., 112475.Onderzoeksoutput: Article › peer review
Open AccessBestand1 Citaat (Scopus)1 Downloads (Pure)
Prijzen
-
ASH abstract Achievement Award 2014
De Veirman, Kim (Recipient), 6 dec 2014
Prijs: National/international honour
-
ASH abstract Achievement Award 2019
De Veirman, Kim (Recipient), 2019
Prijs: National/international honour
-
Development of a nanoCAR-T cell approach for the treatment of multiple myeloma
Hanssens, Heleen (Recipient), Devoogdt, Nick (Recipient), De Veirman, Kim (Recipient) & Breckpot, Karine (Recipient), 15 dec 2021
Prijs: Fellowship awarded competitively
-
Poster award Belgian Hematological Society 30th Annual General Meeting 2015
De Veirman, Kim (Recipient), 29 jan 2015
Prijs: National/international honour
-
Prijs Dr. Karel-Lodewijk Verleysen 2018 ter bekroning van medisch onderzoekswerk aan de Vrije Universiteit Brussel
De Veirman, Kim (Recipient), 9 dec 2019
Prijs: Prize (including medals and awards)
Activiteiten
-
Mapping the immune heterogeneity within the myeloma microenvironment using single-cell transcriptomics
Emma Verheye (Speaker), Rong Fan (Contributor), Hatice Satilmis (Contributor), Niels Vandewalle (Contributor), Pauline Bardet (Contributor), Emile Clappaert (Contributor), Daliya Kancheva (Contributor), Elke De Bruyne (Contributor), Karin Vanderkerken (Contributor), Kim De Veirman (Contributor) & Damya Laoui (Contributor)
3 feb 2023Activiteit: Talk or presentation at a conference
-
AXL targeting using Bemcentinib increases chemosensitivity in Acute Myeloid Leukemia
Niels Vandewalle (Speaker), Laura Meysman (Contributor), Nathan De Beule (Contributor), Ann De Becker (Contributor), Hatice Satilmis (Contributor), Emma Verheye (Contributor), Rong Fan (Contributor), Elke De Bruyne (Contributor), Eline Menu (Contributor), Karin Vanderkerken (Contributor), Karine Breckpot (Contributor), Nick Devoogdt (Contributor) & Kim De Veirman (Contributor)
3 feb 2023Activiteit: Talk or presentation at a conference
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Inge Oudaert (Speaker), Eline Menu (Contributor) & Kim De Veirman (Contributor)
29 jan 2021 → 30 jan 2021Activiteit: Talk or presentation at a conference
-
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers (BHS Gam 2020)
Kim De Veirman (Presenter)
14 feb 2020 → 16 feb 2020Activiteit: Talk or presentation at a conference
-
Bone marrow microenvironment and MGUS progression (Bari, Italy)
Kim De Veirman (Invited speaker)
5 nov 2020 → 7 nov 2020Activiteit: Talk or presentation at a conference
Scriptie
-
Assessment of antigen-binding domain parameters important for adequate CAR-T-cell activation: evaluating different SLAMF7-targeting nanobodies.
Auteur: Meeus, F., Hanssens, H., De Veirman, K. & Devoogdt, N., 19 jun 2020Begeleider: Hanssens, H. (Advisor)
Scriptie/Masterproef: Master's Thesis
-
AXL and CS1: New targets in myeloma cell dormancy
Auteur: De Veirman, K. & Benalla, S., 21 jun 2018Scriptie/Masterproef: Master's Thesis
-
Development of a NanoCAR approach for the treatment of multiple myeloma
Auteur: Devoogdt, N., Breckpot, K., De Veirman, K. & Hanssens, H., 2022Scriptie/Masterproef: Doctoral Thesis
-
Mesenchymal Stromal Cell induced hedgehog signaling in Multiple Myeloma and its role in drug resistance
Auteur: De Veirman, K. & Terwecoren, D., 2013Scriptie/Masterproef: Master's Thesis
-
Nanobody-based individualized AXL targeting to reverse immune suppression and overcome therapy resistance in Acute Myeloid Leukemia.
Auteur: De Veirman, K., Breckpot, K., Devoogdt, N. & Kerre, T., 2024Scriptie/Masterproef: Doctoral Thesis